The purpose of this study is to evaluate the Pharmacokinetics and safety of Ravidasvir in Combination with Ritonavir-boosted Danoprevir in Single and Multiple doses in Healthy Participants
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
18
Ravidasvir tablet administered orally 200mg QD on day 1, 13 - 23
Danoprevir tablet administered orally 100mg QD on day 7 and 13, 100mg BID on day 14-22, 100mg QD on day 23
Ritonavir tablet administered orally 100mg QD on day 7 and 13, 100mg BID on day 14-22, 100mg QD on day 23
Safety: Incidence of adverse events
Time frame: 40 days
Pharmacokinetics: Maximum plasma concentration at steady-state (Css,max)
Time frame: Up to 24 weeks
Pharmacokinetics: Total area under the concentration-time curve form time 0 to 12 hours post-dose at steady-state
Time frame: Up to 24 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Placebo